NCT07455513 A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer
| NCT ID | NCT07455513 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Cigarette Smoking-Related Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-02-25 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2026-02-25 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates the feasibility of a novel tobacco cessation resource called a Buckeye Quit Stick among smokers with a diagnosed or suspected thoracic cancer. Tobacco use is the single most preventable cause of disease, disability, and death in the United States. While the benefits of quitting smoking are numerous, rates of persistent smoking after cancer diagnosis remain high. Research has found that patients who quit smoking but subsequently relapse frequently report the hand/oral habit as a barrier to sustained smoking cessation. The Buckeye Quit Stick is an innovative cessation aid designed to directly address patients' hand/oral habit by substituting the cessation aid for cigarettes without integrating pharmacologic intervention, which is typically managed by their medical provider and may require direct supervision due to the patient's health status. The Buckeye Quit Stick is designed to satisfy the repeated hand/oral pattern or ritual, thereby avoiding the physical loss of holding a cigarette in the hand or mouth and the action of smoking. It may also help occupy fidgeting hands and potentially reduce stress and cravings. This novel cessation resource may address key factors that influence smoking abstinence and improve patients' health outcomes.
Eligibility Criteria
Inclusion Criteria: * \>= 21 years old * Speak and understand English * Established patient of the OSU thoracic clinics * Diagnosed with a thoracic malignancy or has a clinically suspected thoracic malignancy as documented by treating provider * Willing and able to participate in the study protocol (e.g., complete the survey and related study documents and provide informed consent) * Current self-reported smoker * Willingness to change = score of above 1 on the Stages of Change measure Exclusion Criteria: * \< 21 years old (Ohio is a tobacco 21 state.) * Patient outside of the OSU clinics (This intervention targets patients who may benefit the most from cessation.) * Unwilling or unable to provide consent or complete study components * Prisoners will be excluded from participation
Contact & Investigator
The Ohio State University Comprehensive Cancer Center
✉ OSUCCCClinicaltrials@osumc.edu📞 800-293-5066
Logan Roof, MD, MS
PRINCIPAL INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT07455513 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Cigarette Smoking-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07455513 currently recruiting?
Yes, NCT07455513 is actively recruiting participants. Contact the research team at OSUCCCClinicaltrials@osumc.edu for enrollment information.
Where is the NCT07455513 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT07455513 clinical trial?
NCT07455513 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Logan Roof, MD, MS at Ohio State University Comprehensive Cancer Center. The trial plans to enroll 30 participants.